Probing the binding sites and mechanisms of action of two human Ether-a-go-go-related gene channel activators, 1,3-bis-(2-Hydroxy-5- trifluoromethyl-phenyl)-urea (NS1643) and 2-[2-(3,4-Dichloro-phenyl)-2,3- dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD307243)

Molecular Pharmacology

Volumn 73, Issue 6, 2008, Pages 1709-1721

  Xu, Xulin ^a   Recanatini, Maurizio ^b   Roberti, Marinella ^b   Tseng, Gea Ny ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 BIS(2 HYDROXY 5 TRIFLUOROMETHYLPHENYL)UREA; 2 [2 (3,4 DICHLOROPHENYL) 2,3 DIHYDRO 1H ISOINDOL 5YLAMINO] NICOTINIC ACID; CYSTEINE; DOFETILIDE; NICOTINIC ACID DERIVATIVE; NS 1643; PD 307243; POTASSIUM CHANNEL HERG; POTASSIUM ION; UREA DERIVATIVE;

ANIMAL CELL; ARTICLE; CELL MEMBRANE; CELL STRAIN COS7; CHANNEL GATING; CONTROLLED STUDY; DRUG BINDING SITE; DRUG MECHANISM; DRUG SELECTIVITY; KINETICS; MALE; NONHUMAN; OOCYTE; PRIORITY JOURNAL;

ANIMALS; BINDING SITES; CERCOPITHECUS AETHIOPS; COS CELLS; CRESOLS; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; GUINEA PIGS; HUMANS; ISOINDOLES; MALE; NICOTINIC ACIDS; PHENYLUREA COMPOUNDS; XENOPUS;

EID: 44249098289     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.108.045591     Document Type: Article

References (33)

1. Ahern CA, Eastwood AL, Lester HA, Dougherty DA, and Horn R (2006) A cation-π interaction between extracellular TEA and an aromatic residue in potassium channels. J Gen Physiol 128:649-657.
2. Brugada R, Hong K, Dumaine R, Cordeiro JM, Gaita F, Borggrefe M, Menendez TM, Brugada J, Pollevick GD, Wolpert C, et al. (2004) Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation 109:30-35.
3. Casis O, Olesen SP, and Sanguinetti MC (2006) Mechanism of action of a novel human ether-a-go-go-related gene channel activator. Mol Pharmacol 69:658-665.
4. Dun W, Jiang M, and Tseng GN (1999) Allosteric effects of mutations in the extracellular S5-P loop on the gating and ion permeation properties of hERG. Pflugers Arch 439:141-149.
5. Fan JS, Jiang M, Dun W, McDonald TV, and Tseng GN (1999) Effects of outer mouth mutations on hERG channel function: a comparison with similar mutations in Shaker. Biophys J 76:3128-3140.
6. + channel voltage-sensing domain. Neuron 40:515-525.
7. Gordon E, Lozinskaya IM, Lin Z, Seus SF, Blaney FE, Willette RN, and Xu X. (2008) 2-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]- nicotinic acid (PD-307243) causes instantaneous current through human ether-a-go-go-related gene potassium channels. Mol Pharmacol 73:639-651.
8. Hansen RS, Diness TG, Christ T, Demnitz J, Ravens U, Olesen SP, and Grunnet M (2006) Activation of human ether-a-go-go-related gene potassium channels by the diphenylurea 1,3-bis-(2-hydroxy-5-trifluoromethy-phenyl)-urea (NS1643). Mol Pharmacol 69:266-277.
9. Jiang M, Zhang M, Maslennikov IV, Liu J, Wu DM, Korolkova YV, Arseniev AS, Grishin EV, and Tseng GN (2005) Dynamic conformational changes of extracellular S5-P linkers in the hERG channel. J Physiol 569:75-89.
10. Kamiya K, Niwa R, Mitcheson JS, and Sanguinetti MC (2006) Molecular determinants of hERG channel block. Mol Pharmacol 69:1709-1716.
11. + channel. Mol Pharmacol 67:827-836.
12. Lainé M, Lin MCA, Bannister JPA, Silverman WR, Mock AF, Roux B, and Papazian DM (2003) Atomic proximity between S4 segment and pore domain in Shaker potassium channels. Neuron 39:467-481.
13. Lenaeus MJ, Vamvouka M, Focia PJ, and Gross A (2005 Structural basis of TEA blockade in a model potassium channel. Nat Struct Mol Biol 12:454-459.
14. Liu J, Zhang M, Jiang M, and Tseng GN (2002) Structural and functional role of the extracellular S5-P linker in the HERG potassium channel. J Gen Physiol 120:723-737.
15. Long SB, Campbell EB, and MacKinnon R (2005) Voltage sensor of Kv1.2: structural basis of electromechanical coupling. Science 309:903-908.
16. López-Barneo J, Hoshi T, Heinemann SH, and Aldrich RW (1993) Effects of external cations and mutations in the pore region on C-type inactivation of Shaker potassium channels. Receptors Channels 1:61-71.
17. Pardo-Lopez L, Zhang M, Liu J, Jiang M, Possani LD, and Tseng GN (2002) Mapping the binding site of a HERG-specific peptide toxin (ErgTx) to the channel's outer vestibule. J Biol Chem 277:16403-16411.
18. Perry M, Saches FB, and Sanguinetti MC (2007) Structural basis of action of a human ether-a-go-go-related gene 1 potassium channel activator. Proc Natl Acad Sci U S A 104:13827-13832.
19. + channel blockade: current knowledge and strategies for the early prediction during drug development. Med Res Rev 25:133-166.
20. Roden DM (2004) Drug-induced prolongation of the QT interval. N Engl J Med 350:1013-1022.
21. Kr potassium channel. Cell 81:299-307.
22. + current. Differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol 96:195-215.
23. Schreibmayer W, Lester HA, and Dascal N (1994) Voltage clamping of Xenopus laevis oocytes utilizing agarose-cushion electrodes. Pflugers Arch 426:453-458.
24. Smith PL, Baukrowitz T, and Yellen G. The inward rectification mechanism of the HERG cardiac potassium channel. Nature 379:833-836, 1996.
25. + channel S5P extracellular linker: role of an amphipathic α-helix in C-type inactivation. J Biol Chem 278:42136-42148.
26. Kr: the hERG channel. J Mol Cell Cardiol 33:835-849.
27. Tseng GN, Sonawane KD, Korolkova YV, Zhang M, Liu J, Grishin E, and Guy HR (2007) Probing outer mouth structure of the hERG channel with peptide toxin foot printing and molecular modeling. Biophys J 92:3524-3540.
28. Wang S, Liu S, Morales MJ, Strauss HC, and Rasmusson RL (1997) A quantitative analysis of the activation and inactivation kinetics of HERG expressed in Xenopus oocytes. J Physiol 502:45-60.
29. Yao JA, Jiang M, Fan JS, Zhou YY, and Tseng GN (1999) Heterogeneous changes in K currents in rat ventricles three days after myocardial infarction. Cardiovasc Res 44:132-145.
30. + channel. Role of S6 in antiarrhythmic drug binding. Circ Res 78:1105-1114.
31. Zhang H, Zhu B, Yao JA, and Tseng GN (1998) Differential effects of S6 mutations on binding of quinidine and 4-aminopyridine to rKv1.4: common site but different factors in determining blockers' binding affinity. J Pharmacol Exp Ther 287:332-343.
32. Zhang M, Korolkova YV, Liu J, Jiang M, Grishin EV, and Tseng GN (2003) BeKm-1 is a hERG-specific toxin that shares the structure with ChTx but the mechanism of action with ErgTx1. Biophys J 84:3022-3036.
33. Zhou J, Augelli-Szafran CE, Bradley JA, Chen X, Koci BJ, Volberg WA, Sun Z, and Cordes JS (2005) Novel potent human ether-a-go-go-related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity. Mol Pharmacol 68:876-884.